Artificial General Intelligence for the Detection of Neurodegenerative Disorders

Review

. 2024 Oct 16;24(20):6658.

doi: 10.3390/s24206658.

Affiliations

Item in Clipboard

Review

Yazdan Ahmad Qadri et al.

Sensors (Basel).

2024.

Abstract

Parkinson’s disease and Alzheimer’s disease are among the most common neurodegenerative disorders. These diseases are correlated with advancing age and are hence increasingly becoming prevalent in developed countries due to an increasingly aging demographic. Several tools are used to predict and diagnose these diseases, including pathological and genetic tests, radiological scans, and clinical examinations. Artificial intelligence is evolving to artificial general intelligence, which mimics the human learning process. Large language models can use an enormous volume of online and offline resources to gain knowledge and use it to perform different types of tasks. This work presents an understanding of two major neurodegenerative disorders, artificial general intelligence, and the efficacy of using artificial general intelligence in detecting and predicting these neurodegenerative disorders. A detailed discussion on detecting these neurodegenerative diseases using artificial general intelligence by analyzing diagnostic data is presented. An Internet of Things-based ubiquitous monitoring and treatment framework is presented. An outline for future research opportunities based on the challenges in this area is also presented.

Keywords:

Alzheimer’s disease; Internet of Things; Parkinson’s disease; artificial general intelligence; large language models.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

**Figure 2**

Transformer architecture described in [61]. An encoder and a decoder with positional encoding enable the attention mechanism.

**Figure 3**

Diagnosing NDs using AGI. Summary of Section 3.

**Figure 4**

Monitoring and managing symptoms by converging the IoT and AI. An IoT-based framework is proposed to detect PD symptoms and alleviate symptoms using controlled administration of DBS and drugs.

References

1. Parr N. Immigration and the prospects for long-run population decreases in European countries. Vienna Yearb. Popul. Res. 2023;21:181–209. doi: 10.1553/p-8jf5-7cdc.
  
  –
  
  DOI
1. Jung K.S. 2024 National Health Insurance & Long-Term Care Insurance System Republic of Korea. [(accessed on 20 July 2024)]. Available online: https://www.nhis.or.kr/english/wbheaa03500m01.do?mode=download&articleNo….
1. Kim S.H., Park J.E. The Rising Prevalence of Parkinson’s Disease in South Korea. J. Clin. Neurol. 2021;17:123–130.
1. Kang S.H., Moon S.J., Kang M., Chung S.J., Cho G.J., Koh S.B. Incidence of Parkinson’s disease and modifiable risk factors in Korean population: A longitudinal follow-up study of a nationwide cohort. Front. Aging Neurosci. 2023;15:1094778. doi: 10.3389/fnagi.2023.1094778.
  
  –
  
  DOI
  
  –
  
  PMC
  
  –
  
  PubMed
1. Xu T., Dong W., Liu J., Yin P., Wang Z., Zhang L., Zhou M. Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021: Findings from the global burden of disease study 2021. Lancet Reg. Health-West. Pac. 2024;19:658–670. doi: 10.1016/j.lanwpc.2024.101078.
  
  –
  
  DOI
  
  –
  
  PMC
  
  –
  
  PubMed